GlassScriptPhysician profile
Anne M Noonan
NPI 1477887479
$25,256.86
in general payments reported to CMS, 2019-2025
17 companies · $8,781 in 2025
The $8,781 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,399 · 2021: $1,563 · 2022: $51.81 · 2023: $4,884 · 2024: $5,579 · 2025: $8,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,296 · Food and Beverage: $1,051 · Education: $51.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,845.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,296.00 |
| Food and Beverage | $1,051.49 |
| Education | $51.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $11,431.80 | 2022-2025 | Imfinzi |
| Exelixis INC. | $4,165.94 | 2019 | |
| Jazz Pharmaceuticals INC. | $3,296.00 | 2025 | |
| Taiho Oncology, INC. | $2,114.00 | 2023 | |
| Astrazeneca Uk Limited | $2,055.00 | 2023 | |
| Eisai INC. | $1,642.95 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $166.08 | 2019-2025 | Keytruda |
| Array Biopharma INC | $138.67 | 2024 | |
| Pfizer INC. | $104.99 | 2024 | |
| Janssen Scientific Affairs, LLC | $103.84 | 2025 | Rybrevant |
| Genentech USA, INC. | $37.59 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Noonan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.